Luye Closes $269 Million Acquisition of Swiss Pharma's Patch Business

Luye Pharma has closed its $269 million acquisition of Acino's transdermal drug delivery business, which it announced earlier this year. Acino, a Swiss company, offers high-margin, difficult-to-make transdermal patch products for niche markets that include CNS, pain and hormone indications. Luye positioned the transaction as a two-way street: it will bring Acino's products and technology to the China market, while it also uses Acino's expertise with non-China markets to export its China drug portfolio. More details.... Stock Symbol: (HK: 2186) Share this with colleagues: // //